Bookmark and Share
BioAssay: AID 1267

Confirmation cell-based high throughput screening assay to measure STAT3 activation

The signal transducer and activator of transcription (STAT) family of transcription factors transduce signals from a variety of extracellular stimuli and are important mediators of inflammation, cell survival, differentiation, and proliferation (1, 2). STATs are activated in response to growth factors, cytokines, and G-CSF binding to cell surface receptor tyrosine kinases (1-3). In resting more ..
_
   
 Tested Compounds
 Tested Compounds
All(1197)
 
 
Active(767)
 
 
Inactive(430)
 
 
 Tested Substances
 Tested Substances
All(1197)
 
 
Active(767)
 
 
Inactive(430)
 
 
AID: 1267
Data Source: The Scripps Research Institute Molecular Screening Center (STAT3_POT_LUC_1536_3X%ACT)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Screening Center Network
BioAssay Version:
Deposit Date: 2008-05-07
Modify Date: 2008-09-15

Data Table ( Complete ):           Active    All
Target
BioActive Compounds: 767
Depositor Specified Assays
AIDNameTypeProbeComment
862Primary cell-based high throughput screening assay to measure STAT3 inhibitionscreening
871Primary cell-based high throughput screening assay to measure STAT3 activationscreening
932Primary cell-based high throughput screening assay to measure STAT1 activationscreening
1406Dose response counterscreen assay for STAT3 activators: cell-based high throughput assay to measure STAT1 activationconfirmatory
1398Dose response cell-based assay to measure STAT3 activationconfirmatory
2049Late stage results from the probe development effort to identify activators of signal transducer and activator of transcription 3 (STAT3).screening
1805Summary of probe development efforts to identify activators of signal transducer and activator of transcription 3 (STAT3)summary2
Description:
Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: David Frank, Dana Farber Cancer Institute
Network: Molecular Library Screening Center Network (MLSCN)
Grant Proposal Number: 1 X01 MH079826-01
Grant Proposal PI: David Frank

External Assay ID: STAT3_POT_LUC_1536_3X%ACT

Name: Confirmation cell-based high throughput screening assay to measure STAT3 activation

Description:

The signal transducer and activator of transcription (STAT) family of transcription factors transduce signals from a variety of extracellular stimuli and are important mediators of inflammation, cell survival, differentiation, and proliferation (1, 2). STATs are activated in response to growth factors, cytokines, and G-CSF binding to cell surface receptor tyrosine kinases (1-3). In resting cells STATs are inactive in the cytoplasm. In response to stimuli, STATs are phosphorylated by the Janus-activated kinases (Jaks), which induces STAT dimerization and nuclear translocation, where STATs bind to specific enhancer elements in target genes (2). Although structurally similar, the seven STAT family member (STATs 1, 2, 3, 4, 5a, 5b, and 6) possess diverse biological roles (2). For example, STAT1 activation is pro-inflammatory and anti-proliferative, while STAT3 activation is anti-inflammatory and pro-apoptotic (2). STAT1 is largely responsible for mediating the effects of IFN-gamma, while STAT3 is predominantly involved in IL-6 signaling (4). STAT1 induces expression of genes that inhibit the cell cycle, and thus STAT1 is considered to have tumor suppressor properties (5). Studies show that STAT3 is activated in a majority of breast and prostate cancers, and that STAT3 inhibition using RNA interference or a dominant negative leads to reduced cell proliferation, survival, and wound healing (1, 4, 6). Blocking STAT3 interaction with the epidermal growth factor receptor (EGFR) using peptide aptamers has been shown to reduce tumor growth (7). Due to the diverse roles and potent phenotypes associated with STAT signaling, the identification of selective potentiators of STAT3 activity may lead to pharmacological tools for cancer, wound healing, and inflammatory diseases.


References:

1. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005 Jun 15;65(12):5054-62.
2. Schindler C, Levy DE, Decker T. AK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007 Jul 13;282(28):20059-63.
3. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007 Oct 1;13(19):5665-9.
4. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62.
5. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res. 2003 Jun;9(6):2166-72.
6. Takeda, K. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S.1998. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell- specific Stat3-deficient mice. J. Immunol. 161:4652-4660.
7. Buerger C, Nagel-Wolfrum K, Kunz C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J Biol Chem. 2003 Sep 26;278(39):37610-21.

Keywords:

STAT3, signal transducer and activator of transcription 3, acute-phase response factor, APRF, transcription factor, Scripps, Scripps Florida, Molecular Library Screening Center Network, MLSCN, HTS, assay, potentiator, potentiation, activation, activator, U3A, confirmatory, confirmatory screen, luciferase, luminescence, reporter, 1536.
Protocol
Assay Overview:

The purpose of this assay is to confirm activity of a subset of compounds that were identified as active in a previous set of experiments entitled, "Primary cell-based high throughput screening assay to measure STAT3 activation" (PubChem AID 871). The compounds selected for testing in this AID met at least the two following criteria: 1) they were declared active in AID 871; 2) they were declared inactive in a previous set of experiments entitled, "Primary cell-based high throughput screening assay to measure STAT1 activation" (PubChem AID 932).

In this assay activation of STAT3 transcription was measured using a human U3A fibrosarcoma cell line that stably expresses a human STAT3-luciferase construct. This cell line is deficient in STAT1. Test compounds were screened for their ability to increase IL-6-mediated STAT3::luciferase reporter activity. Cells were exposed to test compounds, followed by treatment with IL-6 to activate STAT3 transcription. Changes in STAT3::luciferase activity were monitored by measuring well luminescence. As designed, a STAT3 potentiator will increase IL-6-mediated STAT3 transcription, thus enhancing the activity of the luciferase reporter gene, and increasing well luminescence.

Protocol Summary:

The STAT3 potentiator and antagonist confirmation assays were run simultaneously. U3A cells were grown in T-175 flasks in Dulbecco's Modified Eagle's Media (DMEM) supplemented with 10% v/v fetal bovine serum and antibiotics (50 micrograms/mL each of penicillin and streptomycin, 100 micrograms/mL neomycin) at 37 degrees C in an atmosphere of 5% CO2 and 95% relative humidity (RH).

Prior to the start of the assay, cells were resuspended at a density of 1.88 million cells/mL in phenol red-free growth medium, and filtered through a 0.7 micron filter. Next, 4 ul of cell suspension (7,520 cells per well) were dispensed into each well of 1536-well plates. The assay was started by immediately dispensing 28 nL of test compound (5.7 uM final nominal concentration) in DMSO to sample wells, or DMSO alone (0.6% final concentration) to High Control wells. The plates were then incubated for 1 hour at 37 degrees C (5% CO2, 95% RH). Next, 28 nL of nifuroxazide (100 uM final concentration in DMSO) were added to a subset of control wells, to monitor that the assay was functioning properly. Then, 1 ul of human recombinant IL-6 (33 ng/mL final nominal concentration) was dispensed into sample and control wells. The plates were then incubated for 6 hours at 37 degrees C (5% CO2, 95% RH). The assay was stopped by dispensing 5 ul of SteadyLite HTS luciferase substrate at room temperature to each well, followed by incubation at room temperature for 15 minutes. Luminescence was measured on the ViewLux plate reader.

Prior to % potentiation calculations, luminescence values were corrected by subtracting background luminescence, measured in wells containing media and substrate only. The percent potentiation was defined using the following mathematical formula:

% Potentiation = 100* (Test_Compound/Median_High_Control)

Where:
Test_Compound is defined as the luminescence value of a well containing IL-6 and test compound.

Median_High_Control is defined as the median luminescence value of wells containing IL-6 and DMSO.

Test compounds were assayed in triplicate at a single concentration of 5.7 micromolar. Any compound that exhibited a percent activation greater than the hit cutoff calculated for the Primary screen was declared active. The reported Pubchem_Activity_Score has been normalized to 100% of the highest observed activation. Negative % activation values were assigned an activity score of zero.


List of Reagents:

Dulbecco's Modified Eagle's Media I (Invitrogen, part 11965-092)
Dulbecco's Modified Eagle's Media, no Phenol Red (Invitrogen, part 21063-029)
Fetal Bovine Serum (Hyclone, part SH30088-03)
100X Penicillin-Streptomycin-Neomycin mix (Invitrogen, part 15640-055)
Neomycin B (Sigma-Aldrich, St. Louis, MO, part 33492)
Recombinant human IL-6 (Peprotech, part 200-06)
Nifuroxazide (Sigma-Aldrich, part N2641)
SteadyLite HTS Assay Kit (PerkinElmer, part 6016989)
T175 Flasks (Corning, part 431080)
1536-well plates (Greiner, part 789173)
Comment
Due to the increasing size of the MLSCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon the associated Primary uHTS campaign's specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Each plate was normalized using same-plate controls. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that non-specifically modulate STAT3 or luciferase activity, and compounds that quench or enhance luminescence within the well. All test compound concentrations reported are nominal; the specific concentration for a particular test compound may vary based upon the actual sample provided by the MLSMR. The MLSMR was not able to provide all compounds selected for testing in this AID.

The inactive compounds of this assay have activity score range of 11 to 19 and active compounds range of activity score is 19 to 100.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Potentiation (5.7μM**)Normalized percent activation of the primary screen at a compound concentration of 5.7 micromolar.Float%
2Standard DeviationStandard deviation of the confirmation screen derived from the normalized percent potentiation of the triplicate data for each compound.Float

** Test Concentration.

Data Table (Concise)
Classification
PageFrom: